275 related articles for article (PubMed ID: 26222274)
21. Prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acid.
Saad F; Segal S; Eastham J
Eur Urol; 2014 Jan; 65(1):146-53. PubMed ID: 22633317
[TBL] [Abstract][Full Text] [Related]
22. Molecular alterations and emerging targets in castration resistant prostate cancer.
Lorente D; De Bono JS
Eur J Cancer; 2014 Mar; 50(4):753-64. PubMed ID: 24418724
[TBL] [Abstract][Full Text] [Related]
23. New developments in the imaging of metastatic prostate cancer.
Beauregard JM; Pouliot F
Curr Opin Support Palliat Care; 2014 Sep; 8(3):265-70. PubMed ID: 25004180
[TBL] [Abstract][Full Text] [Related]
24. Hematologic Toxicity From Radium-223 Therapy for Bone Metastases in Castration-Resistant Prostate Cancer: Risk Factors and Practical Considerations.
Jacene H; Gomella L; Yu EY; Rohren EM
Clin Genitourin Cancer; 2018 Aug; 16(4):e919-e926. PubMed ID: 29678471
[TBL] [Abstract][Full Text] [Related]
25. Radionuclide therapy for osseous metastases in prostate cancer.
Abi-Ghanem AS; McGrath MA; Jacene HA
Semin Nucl Med; 2015 Jan; 45(1):66-80. PubMed ID: 25475380
[TBL] [Abstract][Full Text] [Related]
26. Castration-resistant prostate cancer: from new pathophysiology to new treatment.
Sridhar SS; Freedland SJ; Gleave ME; Higano C; Mulders P; Parker C; Sartor O; Saad F
Eur Urol; 2014 Feb; 65(2):289-99. PubMed ID: 23957948
[TBL] [Abstract][Full Text] [Related]
27. Leading causes of castration-resistant prostate cancer.
Lu M; Lu H; Kong Q
Expert Rev Anticancer Ther; 2015 Apr; 15(4):425-32. PubMed ID: 25645203
[TBL] [Abstract][Full Text] [Related]
28. Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up.
Studer UE; Whelan P; Wimpissinger F; Casselman J; de Reijke TM; Knönagel H; Loidl W; Isorna S; Sundaram SK; Collette L;
Eur Urol; 2014 Nov; 66(5):829-38. PubMed ID: 23932338
[TBL] [Abstract][Full Text] [Related]
29. Isotope Therapy for Castrate-Resistant Prostate Cancer: Unique Sequencing and Combinations.
Sartor O
Cancer J; 2016; 22(5):342-346. PubMed ID: 27749328
[TBL] [Abstract][Full Text] [Related]
30. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
31. Androgen-regulated gastrin-releasing peptide receptor expression in androgen-dependent human prostate tumor xenografts.
Schroeder RP; de Visser M; van Weerden WM; de Ridder CM; Reneman S; Melis M; Breeman WA; Krenning EP; de Jong M
Int J Cancer; 2010 Jun; 126(12):2826-34. PubMed ID: 19876914
[TBL] [Abstract][Full Text] [Related]
32. [Molecular targeting drug of kinase inhibitors for castration resistant prostate cancer].
Kosaka T; Oya M
Nihon Rinsho; 2014 Dec; 72(12):2186-92. PubMed ID: 25518356
[TBL] [Abstract][Full Text] [Related]
33. Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer.
Bastos DA; Dzik C; Rathkopf D; Scher HI
Oncology (Williston Park); 2014 Aug; 28(8):693-9. PubMed ID: 25140626
[TBL] [Abstract][Full Text] [Related]
34. 223Ra Dichloride Bone-Targeted Therapy in a Case of Metastatic Salivary Duct Carcinoma.
Manfredi M; Airoldi M; Tucci M; Buttigliero C; Parente A; Angusti T
Clin Nucl Med; 2017 May; 42(5):391-393. PubMed ID: 28166157
[TBL] [Abstract][Full Text] [Related]
35. Current state of castration-resistant prostate cancer.
Petrylak DP
Am J Manag Care; 2013 Dec; 19(18 Suppl):s358-65. PubMed ID: 24494690
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer.
Ahmadzadehfar H; Eppard E; Kürpig S; Fimmers R; Yordanova A; Schlenkhoff CD; Gärtner F; Rogenhofer S; Essler M
Oncotarget; 2016 Mar; 7(11):12477-88. PubMed ID: 26871285
[TBL] [Abstract][Full Text] [Related]
37. Alpha particles as radiopharmaceuticals in the treatment of bone metastases: mechanism of action of radium-223 chloride (Alpharadin) and radiation protection.
Cheetham PJ; Petrylak DP
Oncology (Williston Park); 2012 Apr; 26(4):330-7, 341. PubMed ID: 22655525
[TBL] [Abstract][Full Text] [Related]
38. PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013.
Kulkarni HR; Singh A; Schuchardt C; Niepsch K; Sayeg M; Leshch Y; Wester HJ; Baum RP
J Nucl Med; 2016 Oct; 57(Suppl 3):97S-104S. PubMed ID: 27694180
[TBL] [Abstract][Full Text] [Related]
39. Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models.
Suominen MI; Fagerlund KM; Rissanen JP; Konkol YM; Morko JP; Peng Z; Alhoniemi EJ; Laine SK; Corey E; Mumberg D; Ziegelbauer K; Käkönen SM; Halleen JM; Vessella RL; Scholz A
Clin Cancer Res; 2017 Aug; 23(15):4335-4346. PubMed ID: 28364014
[No Abstract] [Full Text] [Related]
40. Novel strategies in the treatment of castration-resistant prostate cancer (Review).
Marech I; Vacca A; Ranieri G; Gnoni A; Dammacco F
Int J Oncol; 2012 May; 40(5):1313-20. PubMed ID: 22322981
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
